Durham, NC -- (ReleaseWire) -- 10/27/2015 --Arcato Laboratories, developer of OraWaxTM, a revolutionary new treatment for the discomfort caused by orthodontic braces, has been selected to present at the Southeast BIO Investor & Partnering Forum (SEBIO), being held November 11-13, 2015 at the Belmond Charleston Place in Charleston, South Carolina. The presentation will be delivered by Christopher S. Meldrum, President & CEO of Arcato Laboratories.

"The technology platform of Arcato Laboratories is based upon a patented method of delivering a local anesthetic to oral mucosal membranes over a sustained period of time," said Meldrum. "The Arcato technology platform has many applications for other types of pain relief, but the OraWax™ product alone has an estimated market of about $400 million per year," he added.

Celebrating its 17th year, the SEBIO Investor & Partnering Forum has built a loyal following, attracting thought leaders and investors from across the country. To date, the more than 200 later stage and 165 early stage companies that participated in previous SEBIO Investor & Partnering Forums have raised more than $2.5 billion in public and private funding.

Arcato is currently raising $1 million in a Series B round of financing, to complete 510(k) FDA regulatory clearance for OraWax™, and launch the product in the United States.

About Arcato Laboratories
Arcato Laboratories, a leader in the sustained release of anesthetics, is commercializing proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato's first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces).

For more information on investing, please visit our Investor Relations Page.

Contact Christopher S. Meldrum: cmeldrum@arcatolabs.com
Company website: http://www.arcatolabs.com